341 related articles for article (PubMed ID: 16632420)
1. Cell signalling: growth factors and tyrosine kinase receptors.
Perona R
Clin Transl Oncol; 2006 Feb; 8(2):77-82. PubMed ID: 16632420
[TBL] [Abstract][Full Text] [Related]
2. Tyrosine kinases as targets in cancer therapy - successes and failures.
Traxler P
Expert Opin Ther Targets; 2003 Apr; 7(2):215-34. PubMed ID: 12667099
[TBL] [Abstract][Full Text] [Related]
3. ErbB receptor tyrosine kinase inhibitors as therapeutic agents.
Anderson NG; Ahmad T
Front Biosci; 2002 Sep; 7():d1926-40. PubMed ID: 12161338
[TBL] [Abstract][Full Text] [Related]
4. Emerging treatments in oncology: focus on tyrosine kinase (erbB) receptor inhibitors.
Hamid O
J Am Pharm Assoc (2003); 2004; 44(1):52-8. PubMed ID: 14965154
[TBL] [Abstract][Full Text] [Related]
5. Functions of paracrine PDGF signaling in the proangiogenic tumor stroma revealed by pharmacological targeting.
Pietras K; Pahler J; Bergers G; Hanahan D
PLoS Med; 2008 Jan; 5(1):e19. PubMed ID: 18232728
[TBL] [Abstract][Full Text] [Related]
6. The inhibition of tyrosine kinase receptor signalling in leiomyosarcoma cells using the small molecule kinase inhibitor PTK787/ZK222584 (Vatalanib®).
Gaumann AK; Drexler HC; Lang SA; Stoeltzing O; Diermeier-Daucher S; Buchdunger E; Wood J; Bold G; Breier G
Int J Oncol; 2014 Dec; 45(6):2267-77. PubMed ID: 25340839
[TBL] [Abstract][Full Text] [Related]
7. Update on HER-kinase-directed therapy in prostate cancer.
Gross ME; Jo S; Agus DB
Clin Adv Hematol Oncol; 2004 Jan; 2(1):53-6, 64. PubMed ID: 16163160
[TBL] [Abstract][Full Text] [Related]
8. PTK787/ZK 222584, a novel and potent inhibitor of vascular endothelial growth factor receptor tyrosine kinases, impairs vascular endothelial growth factor-induced responses and tumor growth after oral administration.
Wood JM; Bold G; Buchdunger E; Cozens R; Ferrari S; Frei J; Hofmann F; Mestan J; Mett H; O'Reilly T; Persohn E; Rösel J; Schnell C; Stover D; Theuer A; Towbin H; Wenger F; Woods-Cook K; Menrad A; Siemeister G; Schirner M; Thierauch KH; Schneider MR; Drevs J; Martiny-Baron G; Totzke F
Cancer Res; 2000 Apr; 60(8):2178-89. PubMed ID: 10786682
[TBL] [Abstract][Full Text] [Related]
9. Heregulin selectively upregulates vascular endothelial growth factor secretion in cancer cells and stimulates angiogenesis.
Yen L; You XL; Al Moustafa AE; Batist G; Hynes NE; Mader S; Meloche S; Alaoui-Jamali MA
Oncogene; 2000 Jul; 19(31):3460-9. PubMed ID: 10918604
[TBL] [Abstract][Full Text] [Related]
10. Anti-epidermal growth factor receptor strategies for advanced breast cancer.
Campos SM
Cancer Invest; 2008 Oct; 26(8):757-68. PubMed ID: 18853311
[No Abstract] [Full Text] [Related]
11. PDGF receptors as targets in tumor treatment.
Ostman A; Heldin CH
Adv Cancer Res; 2007; 97():247-74. PubMed ID: 17419949
[TBL] [Abstract][Full Text] [Related]
12. Targeting the HER-kinase axis in cancer.
Gross ME; Shazer RL; Agus DB
Semin Oncol; 2004 Feb; 31(1 Suppl 3):9-20. PubMed ID: 15052539
[TBL] [Abstract][Full Text] [Related]
13. SU14813: a novel multiple receptor tyrosine kinase inhibitor with potent antiangiogenic and antitumor activity.
Patyna S; Laird AD; Mendel DB; O'farrell AM; Liang C; Guan H; Vojkovsky T; Vasile S; Wang X; Chen J; Grazzini M; Yang CY; Haznedar JO; Sukbuntherng J; Zhong WZ; Cherrington JM; Hu-Lowe D
Mol Cancer Ther; 2006 Jul; 5(7):1774-82. PubMed ID: 16891463
[TBL] [Abstract][Full Text] [Related]
14. ErbB/HER receptor family in breast cancer--the more we search the more we learn.
Karamouzis MV; Konstantinopoulos PA; Papavassiliou AG
Ann Oncol; 2008 May; 19(5):1020-1. PubMed ID: 18356136
[No Abstract] [Full Text] [Related]
15. Cellular source and amount of vascular endothelial growth factor and platelet-derived growth factor in tumors determine response to angiogenesis inhibitors.
Sennino B; Kuhnert F; Tabruyn SP; Mancuso MR; Hu-Lowe DD; Kuo CJ; McDonald DM
Cancer Res; 2009 May; 69(10):4527-36. PubMed ID: 19401451
[TBL] [Abstract][Full Text] [Related]
16. Vascular endothelial growth factor and vascular endothelial growth factor receptor inhibitors as anti-angiogenic agents in cancer therapy.
Veeravagu A; Hsu AR; Cai W; Hou LC; Tse VC; Chen X
Recent Pat Anticancer Drug Discov; 2007 Jan; 2(1):59-71. PubMed ID: 18221053
[TBL] [Abstract][Full Text] [Related]
17. VEGF receptor signaling in tumor angiogenesis.
McMahon G
Oncologist; 2000; 5 Suppl 1():3-10. PubMed ID: 10804084
[TBL] [Abstract][Full Text] [Related]
18. Roles of ERBB family receptor tyrosine kinases, and downstream signaling pathways, in the control of cell growth and survival.
Grant S; Qiao L; Dent P
Front Biosci; 2002 Feb; 7():d376-89. PubMed ID: 11815285
[TBL] [Abstract][Full Text] [Related]
19. Cell biology of lymphatic metastasis. The potential role of c-erbB oncogene signalling.
Eccles SA
Recent Results Cancer Res; 2000; 157():41-54. PubMed ID: 10857161
[TBL] [Abstract][Full Text] [Related]
20. Vascular endothelial growth factor receptors: expression and function in solid tumors.
Wey JS; Stoeltzing O; Ellis LM
Clin Adv Hematol Oncol; 2004 Jan; 2(1):37-45. PubMed ID: 16163158
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
